LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListBioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

Sector Healthcare

4.78 4.14

Overview

Share price change

24h

Current

Min

4.62

Max

4.87

Key metrics

By Trading Economics

Income

39M

-36M

Sales

6.7M

93M

EPS

-0.28

Profit margin

-41.674

Employees

536

EBITDA

-20M

Recommendations

By TipRanks

Rating Consensus

StrongBuy

12 Months Forecast

+219.78 upside

Dividends

By Dow Jones

Next earnings

1 May 2024

Market Stats

By TradingEconomics

Market Cap

-93M

948M

Previous open

0.64

Previous close

4.78

News Sentiment

By Acuity

50%

50%

127 / 274 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

BioCryst Pharmaceuticals Inc chart

Related News

9 Apr 2024, 17:57 UTC

Major Market Movers

Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration

9 Apr 2024, 17:35 UTC

Acquisitions, Mergers, TakeOvers

Blockchain Coinvestors to Take Linqto Public in $700 Million Deal

9 Apr 2024, 23:52 UTC

Market Talk

Metallurgical Coal Prices May Be Stronger Than Investors Think -- Market Talk

9 Apr 2024, 23:46 UTC

Market Talk

Australian Insurers Likely to Maintain Double-Digit Repricing -- Market Talk

9 Apr 2024, 22:54 UTC

Market Talk

Global Equities Roundup: Market Talk

9 Apr 2024, 22:54 UTC

Market Talk

Regis's McPhillamys Gold Project Still Attractive -- Market Talk

9 Apr 2024, 21:21 UTC

Top News

GM's Cruise Attempts Comeback for Its Driverless Fleet -- With Human Drivers First -- WSJ

9 Apr 2024, 21:10 UTC

Top News

Heard on the Street: Blackstone Bets on Wealthy Renters -- WSJ

9 Apr 2024, 21:00 UTC

Market Talk

Mexican Peso Weakens After Soft CPI; Stocks Close Lower --Market Talk -- Market Talk

9 Apr 2024, 20:37 UTC

Top News

S&P 500 Rises Ahead of Inflation Data -- WSJ

9 Apr 2024, 20:35 UTC

Top News

Boeing Engineer Says Company Used Shortcuts to Fix 787 Jets -- 3rd Update

9 Apr 2024, 20:10 UTC

Acquisitions, Mergers, TakeOvers

Global Partners: With Combined Shell Capacity of Approximately 3.0M Barrels, Terminals Expand Global's Ability to Store and Distribute Gasoline, Distillates, Ethanol >GLP

9 Apr 2024, 20:10 UTC

Acquisitions, Mergers, TakeOvers

Global Partners: Liquid Energy Terminals Located in Chelsea, Mass., New Haven, Conn., Linden, N.J., and Woodbury, N.J. >GLP

9 Apr 2024, 20:10 UTC

Acquisitions, Mergers, TakeOvers

Global Partners LP: Completes Acquisition of Four Liquid Energy Terminals From Gulf Oil

9 Apr 2024, 20:03 UTC

Acquisitions, Mergers, TakeOvers

Berkshire Hathaway's Warrants for Occidental Are Back in the Money With Energy Rally -- Barrons.com

9 Apr 2024, 19:20 UTC

Top News

Boeing Engineer Says Company Used Shortcuts to Fix 787 Jets -- 2nd Update

9 Apr 2024, 19:15 UTC

Market Talk

Oil Futures Post Losses, While Market Remains Bullish -- Market Talk

9 Apr 2024, 19:08 UTC

Top News

Google Expands In-House Chip Efforts in Costly AI Battle -- 2nd Update

9 Apr 2024, 19:02 UTC

Market Talk

Moody's Cuts British Columbia Outlook on Worry Over Fiscal Policy -- Market Talk

9 Apr 2024, 18:57 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

9 Apr 2024, 18:25 UTC

Earnings

Most of the Magnificent Seven Look Set for Strong Earnings -- Barrons.com

9 Apr 2024, 18:11 UTC

Market Talk

Canada May Need To Curtail Public-Sector Payrolls To Finance Spending Needs -- Market Talk

9 Apr 2024, 17:49 UTC

Market Talk

U.S. Investors Brace for Potential Inflation Surprise -- Market Talk

9 Apr 2024, 17:14 UTC

Top News

Boeing Engineer Says Company Used Shortcuts to Fix 787 Jets -- WSJ

9 Apr 2024, 17:11 UTC

Market Talk

EIA Raises Oil Price Estimates On Geopolitical Risk, Supply Restraint -- Market Talk

9 Apr 2024, 16:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 Apr 2024, 16:49 UTC

Market Talk

Canada Immigration Limits to Provide Marginal Relief on Shelter Inflation -- Market Talk

9 Apr 2024, 16:24 UTC

Market Talk

Grain Traders Watching Gold Movements -- Market Talk

9 Apr 2024, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Apr 2024, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc forecast

Price Target

By TipRanks

219.78% upside

12 Months Forecast

Average 14.71 USD  219.78%

High 30 USD

Low 6 USD

Based on 7 Wall Street analysts offering 12 month price targets for BioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

StrongBuy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.1 / 7.65 Support&Resistance

Short Team

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

127 / 274 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.